Viatris Completes $1.69 Billion Acquisition of Pacira BioSciences for Pain Management
Viatris Inc. (VTRS) completes its $1.69 billion acquisition of Pacira BioSciences, establishing a leading position in the non-opioid pain management market.
ALFA USA News
Straight from the SEC filing
Every SEC filing by Viatris Inc that we have reported, newest first. Each story links the original filing.
Reference market data from a third-party provider, as of the most recent story (17 Nov 2026). Not a valuation or a recommendation.
Up 13.6% over the last month ($18.26 on 19 Oct → $20.74 on 16 Nov). Daily closing prices. Source: Yahoo Finance.
| 19 Oct | $18.26 |
|---|---|
| 20 Oct | $18.65 |
| 21 Oct | $18.45 |
| 22 Oct | $18.48 |
| 23 Oct | $18.00 |
| 26 Oct | $18.29 |
| 27 Oct | $18.72 |
| 28 Oct | $18.77 |
| 29 Oct | $19.20 |
| 30 Oct | $19.04 |
| 2 Nov | $18.67 |
| 3 Nov | $18.92 |
| 4 Nov | $19.22 |
| 5 Nov | $18.97 |
| 6 Nov | $19.91 |
| 9 Nov | $20.49 |
| 10 Nov | $20.85 |
| 11 Nov | $21.06 |
| 12 Nov | $20.67 |
| 13 Nov | $20.82 |
| 16 Nov | $20.74 |
Viatris Inc. (VTRS) completes its $1.69 billion acquisition of Pacira BioSciences, establishing a leading position in the non-opioid pain management market.
Viatris Inc. (VTRS) enters definitive agreement to acquire Pacira BioSciences for $36.50 per share in cash, a $1.65 billion deal expected to close by end of 2026.
Track Viatris Inc live
Get the next Viatris Inc SEC filing seconds after it lands.